Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study

1. Burton JR Jr, Rosen HR. Acute rejection in HCV-infected liver transplant recipients: the great conundrum. Liver Transpl. 2006;12(11 Suppl 2):S38–47.

2. Rodríguez-Perálvarez M, Germani G, Papastergiou V, Tsochatzis E, Thalassinos E, Luong TV, et al. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. J Hepatol. 2013;58(2):262–70. doi: 10.1016/j.jhep.2012.09.019 23023010

3. Rodríguez-Perálvarez M, Germani G, Darius T, Lerut J, Tsochatzis E, Burroughs AK. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. Am J Transplant. 2012;12(10):2797–814. doi: 10.1111/j.1600-6143.2012.04140.x 22703529

4. Crettol S, Venetz J-P, Fontana M, Aubert J-D, Ansermot N, Fathi M, et al. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics. 2008;18(4):307–15. doi: 10.1097/FPC.0b013e3282f7046f 18334915

5. Falck P, Åsberg A, Guldseth H, Bremer S, Akhlaghi F, Reubsaet JL, et al. Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients. Transplantation. 2008;85(2):179–84. doi: 10.1097/TP.0b013e31815feede 18212621

6. Rianthavorn P, Ettenger RB, Malekzadeh M, Marik JL, Struber M. Noncompliance with immunosuppressive medications in pediatric and adolescent patients receiving solid-organ transplants. Transplantation. 2004;77(5):778–82. 15021848

7. Kim WR, Lake JR, Smith JM, Keans MA, Schladt DP et al. Liver. Am J Transplant. 2016;16(Suppl 2):69–98.

8. Oellerich M, Walson P, Beck J, Schmitz J, Kollmar O, Schütz E. Graft-derived cell-free DNA as a marker of transplant graft injury. Ther Drug Monit. 2016;38(Suppl 1):S75–9.

9. Beck J, Bierau S, Balzer S, Andag R, Kanzow P, Schmitz J, et al. Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem. 2013;59(12):1732–41. doi: 10.1373/clinchem.2013.210328 24061615

10. Gielis EM, Ledeganck KJ, De Winter BY, Del Favero J, Bosmans JL, Claas FH, et al. Cell-free DNA: an upcoming biomarker in transplantation. Am J Transplant. 2015;15(10):2541–51. doi: 10.1111/ajt.13387 26184824

11. De Vlaminck I, Valantine HA, Snyder TM, Strehl C, Cohen G, Luikart H, et al. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med. 2014;6(241):241ra77. doi: 10.1126/scitranslmed.3007803 24944192

12. Beck J, Oellerich M, Schulz U, Schauerte V, Reinhard L, Fuchs U, et al. Donor-derived cell-free DNA is a novel universal biomarker for allograft rejection in solid organ transplantation. Transplant Proc. 2015;47(8):2400–3. doi: 10.1016/j.transproceed.2015.08.035 26518940

13. Snyder TM, Khush KK, Valantine HA, Quakea SR. Universal noninvasive detection of solid organ transplant rejection. Proc Natl Acad Sci U S A. 2011;108(15):6229–34. doi: 10.1073/pnas.1013924108 21444804

14. Lo YMD, Tein MSC, Pang CCP, Yeung CK, Tong K-L, Hjelm NM. Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients. Lancet. 1998;351(9112):1329–30. 9643800

15. De Vlaminck I, Martin L, Kertesz M, Patel K, Kowarsky M, Strehl C, et al. Noninvasive monitoring of infection and rejection after lung transplantation. Proc Natl Acad Sci U S A. 2015;112(43):13336–41. doi: 10.1073/pnas.1517494112 26460048

16. Beck J, Schmitz J, Kanzow P, Kollmar O, Oellerich M, Schütz E. Absolute quantification of graft derived cell-free DNA (GcfDNA) early after liver transplantation (LTx) using droplet digital PCR. Clin Chem. 2014;60(10):S194–5.

17. Gordon PM, Khan A, Sajid U, Chang N, Suresh V, Dimnik L, et al. An algorithm measuring donor cell-free DNA in plasma of cellular and solid organ transplant recipients that does not require donor or recipient genotyping. Front Cardiovasc Med. 2016;3:33. doi: 10.3389/fcvm.2016.00033 27713880

18. Grskovic M, Hiller DJ, Eubank LA, Sninsky JJ, Christopherson C, Collins JP, et al. Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients. J Mol Diagn. 2016;18(6):890–902. doi: 10.1016/j.jmoldx.2016.07.003 27727019

19. Hidestrand M, Tomita-Mitchell A, Hidestrand PM, Oliphant A, Goetsch M, Stamm K, et al. Highly sensitive noninvasive cardiac transplant rejection monitoring using targeted quantification of donor-specific cell-free deoxyribonucleic acid. J Am Coll Cardiol. 2014;63(12):1224–6. doi: 10.1016/j.jacc.2013.09.029 24140666

20. Wong D, Moturi S, Angkachatchai V, Mueller R, DeSantis G, van den Boom D, et al. Optimizing blood collection, transport and storage conditions for cell free DNA increases access to prenatal testing. Clin Biochem. 2013;46(12):1099–104. doi: 10.1016/j.clinbiochem.2013.04.023 23643886

21. Oellerich M, Beck J, Kanzow P, Schmitz J, Kollmar O, Walson PD, et al. Graft-derived cell-free DNA as a marker of graft integrity after transplantation. In: Oellerich M, Dasgupta A, editors. Personalized immunosuppression in transplantation. 1st ed. Burlington: Elsevier Science; 2015. pp. 153–76.

22. Kanzow P, Kollmar O, Schütz E, Oellerich M, Schmitz J, Beck J, et al. Graft-derived cell-free DNA as an early organ integrity biomarker after transplantation of a marginal HELLP syndrome donor liver. Transplantation. 2014;98(5):e43–5. doi: 10.1097/TP.0000000000000303 25171533

23. Oellerich M, Schütz E, Kanzow P, Schmitz J, Beck J, Kollmar O, et al. Use of graft-derived cell-free DNA as an organ integrity biomarker to reexamine effective tacrolimus trough concentrations after liver transplantation. Ther Drug Monit. 2014;36(2):136–40. doi: 10.1097/FTD.0000000000000044 24452066

24. Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet. 1999;64(1):218–24. doi: 10.1086/302205 9915961

25. Dufour DR. Liver disease. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz textbook of clinical chemistry and molecular diagnostics. 5th ed. London: Elsevier Health Sciences; 2012. pp. 1637–93.

26. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97(10):2614–8. doi: 10.1111/j.1572-0241.2002.06038.x 12385448

27. Sun K, Jiang P, Chan KC, Wong J, Cheng YK, Liang RH, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A. 2015;112(40):E5503–12. doi: 10.1073/pnas.1508736112 26392541

28. Ashoor G, Syngelaki A, Poon LC, Rezende JC, Nicolaides KH. Fetal fraction in maternal plasma cell-free DNA at 11–13 weeks’ gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol. 2013;41(1):26–32. doi: 10.1002/uog.12331 23108725